Clik here to view.
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan...
TOKYO & BASKING RIDGE, N.J. & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a phase 2 study...
View ArticleClik here to view.
InnoCare Announces First Subject Dosed in Clinical Trial of ICP-192 in the U.S.
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States. ICP-192 is a...
View ArticleClik here to view.
武田薬品工業:...
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社は、本日、2020年度第3四半期の業績を公表しましたのでお知らせします。 当社チーフ フィナンシャル オフィサーのコスタ・サルウコスは次のように述べています。...
View ArticleClik here to view.
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020)....
View ArticleClik here to view.
InnoCare Brings On Hillhouse as Strategic Investor, Vivo Capital Increases...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today two subscription agreements with Gaoling and YHG, a company of Hillhouse Capital Group, and Vivo...
View ArticleClik here to view.
InnoCare Announces Approval of Orelabrutinib in Combination with R-CHOP as...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s...
View ArticleClik here to view.
Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its...
CHENGDU, China Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising...
View ArticleClik here to view.
ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation...
HOUSTON ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and...
View ArticleClik here to view.
Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug...
SHANGHAI & GUILFORD, Conn. Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has...
View ArticleClik here to view.
Genetron Health’s Early Liver Cancer Screening Research Results Included in...
BEIJING Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early...
View ArticleClik here to view.
Rhizen Pharmaceuticals AG宣布其合作资产Umbralisib...
瑞士巴塞尔 (美国商业资讯)–专注于肿瘤的临床阶段生物制药公司Rhizen Pharmaceuticals今天宣布，美国FDA已加速核准其新型下一代PI3K-δ抑制剂Umbralisib用于治疗下列疾病，该药已授权给TG Therapeutics (NASDAQ:TGTX)： 先前已接受至少一种基于抗CD20方案的复发或难治边缘区淋巴瘤(MZL)成人患者，以及...
View ArticleClik here to view.
Rhizen...
スイス・バーゼル （ビジネスワイヤ） — オンコロジー分野に傾注する臨床段階のバイオ製薬企業であるRhizen Pharmaceuticalsは本日、TGセラピューティクス（NASDAQ:TGTX）にライセンスした当社の新しい次世代PI3Kデルタ阻害剤Umbralisibが、下記を対象とした治療薬として米国FDAより迅速承認を受けたと発表しました。...
View ArticleClik here to view.
Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference
SYDNEY Australian clinical-stage drug development company, Noxopharm, is pleased to report the publication of the latest survival data from the LuPIN study ahead of their formal presentation to the...
View ArticleClik here to view.
Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据
阿姆斯特丹 Modra Pharmaceuticals (“Modra”)今日公布了其先导产品ModraDoc006/r正在进行的治疗转移性去势抵抗性前列腺癌(mCRPC)...
View ArticleClik here to view.
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the phase 3...
View ArticleClik here to view.
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second cohort (cohort...
View ArticleClik here to view.
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Boston Immune Technologies and Therapeutics and BeiGene Enter into an...
BOSTON & CAMBRIDGE, Mass. & BEIJING Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and...
View ArticleClik here to view.
Clik here to view.
Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer...
BEIJING Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer...
View Article